Navigation Links
Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Date:8/5/2008

om our pivotal Phase III clinical studies of the Isolagen Therapy," said Declan Daly, President and Chief Executive Officer of Isolagen. "We intend to file our Biologics License Application (BLA) with the FDA in early 2009 and continue to progress our ongoing Acne trial. I want to thank the clinical investigators and congratulate the Isolagen team for their exceptional performance and clinical achievement in this groundbreaking pivotal study confirming our belief in this innovative approach to aesthetic skin therapy."

About the Studies

The goal of the Phase III multicenter, double-blind, randomized, placebo- controlled studies was to demonstrate the efficacy of three treatments of Isolagen Therapy compared with placebo in the treatment of bilateral nasolabial folds, or wrinkles, six months following the last study treatment, using the co-primary endpoints of:

-- Subject Wrinkle Satisfaction Assessment: the person's own assessment of the wrinkles using a 5-point wrinkle satisfaction scale, and an

-- Evaluator Wrinkle Severity Assessment: the evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using a 6-point ordinal wrinkle severity scale with a photoguide as a reference tool.

Isolagen's Phase III studies for wrinkles were conducted under the Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) regulations. The SPA process results in an agreement with the FDA that successful clinical trial results will form the basis of an efficacy claim for a marketing application. Although significant, the SPA does not guarantee approval of a BLA.

Further, Isolagen is currently conducting a Phase II/III clinical program to investigate the Isolagen Therapy for the treatment of moderate to severe acne scars.

Investor Conference Call

Isolagen will be hosting an investor conference call and webcast on Wednesday, August 6, 2008 at 8:00 a.m. Eastern Time to discuss the results of t
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
2. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
4. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
5. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
6. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
7. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Financial Officer (CFO), has notified the Board of Directors of his ... new career opportunity as CFO of Severn Trent plc.  James will ... will commence a search for a new CFO immediately. ... helped build and lead a high-quality finance team at Shire. We ...
(Date:10/18/2014)... WASHINGTON , Oct. 18, 2014  In ... Human Rights Campaign (HRC), the nation,s largest lesbian, ... explicitly endorsed the use of Truvada for Pre-Exposure ... health tool used to prevent the spread of ... is the only brand name anti-HIV drug combination ...
(Date:10/17/2014)... 2014  Amgen (NASDAQ: AMGN ) today ... M.D., president of Gladstone Institutes and Gladstone,s Robert W. ... "We are pleased to welcome Dr. Sandy Williams ... Bradway , chairman and chief executive officer of Amgen. ... and his direct experience in our industry will both ...
Breaking Medicine Technology:Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3
... April 26, 2011 The Premier ... U.S. hospitals and 73,000-plus other healthcare sites working together ... Sensus Healthcare, Inc. , the leading provider of FDA-approved ... for millions of skin cancer sufferers, a group purchasing ...
... Cadence Pharmaceuticals, Inc. (NASDAQ: CADX ), a ... products principally for use in the hospital setting, announced ... will present a corporate overview at the following investment ... Deutsche Bank,s 36th Annual Health Care Conference at the ...
Cached Medicine Technology:Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy 2Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy 3
(Date:10/20/2014)... 2014 The Advocator Group, LLC ... the American Foundation for Suicide Prevention’s (AFSP) Out of ... a not-for-profit organization that hosts hundreds of community walks ... events are used to help understand and prevent suicide ... relationships as well. , The Advocator Group shares ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 hc1.com ... a secure cloud solution that enables healthcare organizations ... the ultimate healthcare-specific customer relationship management (“CRM”) solution. ... the unique needs of the healthcare industry, the ... for providers and patients by combining healthcare CRM, ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned company ... absorbent products. The company has recently made efforts ... Tranquility® Premium Protection absorbent products. The company has ... packaging a new look, and is currently working on ... public. , The new website, developed with Thread Marketing ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... 20, 2014 Unveiled at the Sept. 18 ... Scorecard conservatively estimates member hospital ROI on membership dues at ... The Center provides $12.50 in value to member hospitals. The ... – Member Dues)/Member Dues. , “This is the first ... and we think the methodology is really sound,” said ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... a division of Patient Safety Technologies, Inc. (OTC Bulletin Board:,PSTX), ... has become,one of its partners in helping to create a ... sponsor at Leapfrog,s next two meetings in,December and February. , ... and privileged to enter into an affiliation with,Leapfrog. We share ...
... 4 Qforma, an advanced analytics and predictive modeling ... Vice President of Sales, New Business. , ... the pharmaceutical industry and is an ideal addition to Qforma,s ... brings nearly two decades of industry experience and an impressive ...
... ALLEGAN, Mich., Dec. 4 The Perrigo Company,(Nasdaq: ... litigation relating,to Desloratadine tablets (5 mg) has been settled ... Perrigo had been sued for patent infringement of,US Patent ... of an ANDA,containing a Paragraph IV certification. Under ...
... Dec. 4 Decision Resources, one of the,world,s ... and,healthcare issues, finds that Eisai/Helsinn Healthcare,s Aloxi,s marketing,message ... the most influential,by oncologists in the chemotherapy-induced nausea ... with the brand,highlighting the strength of the Aloxi ...
... a,leading provider of managed care market intelligence, reports that ... through the,second quarter of 2008. According to the latest ... be sustained as the economy slows and,healthcare spending decreases. ... is critical in Florida because small businesses,represent about 90 ...
... Dec. 4 Continuing concern over preventable,harm to ... government agency to,emulate a leading aviation safety system. ... the Quality Chasm" series of reports, is,the Patient ... authorized the,creation of Patient Safety Organizations (PSOs). PSOs ...
Cached Medicine News:Health News:SurgiCount Medical Joins The Leapfrog Group 2Health News:Qforma Appoints Kent Harris as Senior Vice President of Sales 2Health News:Perrigo Settles Desloratadine Patent Litigation 2Health News:Perrigo Settles Desloratadine Patent Litigation 3Health News:Oncologists Rank Aloxi's Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market 2Health News:Florida's Small-Group Health Insurance Grew in First Half of 2008, Though Economic Downturn Likely to Halt Upward Trend 2Health News:Florida's Small-Group Health Insurance Grew in First Half of 2008, Though Economic Downturn Likely to Halt Upward Trend 3Health News:Hospitals Now Able to Analyze Medical Mistakes without Fear of Lawsuits 2Health News:Hospitals Now Able to Analyze Medical Mistakes without Fear of Lawsuits 3Health News:Hospitals Now Able to Analyze Medical Mistakes without Fear of Lawsuits 4
Ahmed Glaucoma Valve (small size)....
... established. Provides a robust and durable drainage ... on the globe. Pressure Ridge Molteno Implants ... by Tenons tissue, acts as a Pressure ... range of implants allows the surgeon to ...
... a robust and durable drainage system. Preplaced ... globe. Pressure Ridge Molteno Implants have a ... tissue, acts as a Pressure sensitive biological ... implants allows the surgeon to choose the ...
... Baerveldt Glaucoma Implants feature a low ... and reduced complications. The single-quadrant insertion is ... area seton plate to be installed with ... patented fenestrations of the Baerveldt implant were ...
Medicine Products: